FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4319337483> ?p ?o ?g. }

• W4319337483 endingPage "746" @default.
• W4319337483 startingPage "733" @default.
• W4319337483 abstract "Background Sotorasib is a specific, irreversible inhibitor of the GTPase protein, KRASG12C. We compared the efficacy and safety of sotorasib with a standard-of-care treatment in patients with non-small-cell lung cancer (NSCLC) with the KRASG12C mutation who had been previously treated with other anticancer drugs. Methods We conducted a randomised, open-label phase 3 trial at 148 centres in 22 countries. We recruited patients aged at least 18 years with KRASG12C-mutated advanced NSCLC, who progressed after previous platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor. Key exclusion criteria included new or progressing untreated brain lesions or symptomatic brain lesions, previously identified oncogenic driver mutation other than KRASG12C for which an approved therapy is available (eg EGFR or ALK), previous treatment with docetaxel (neoadjuvant or adjuvant docetaxel was allowed if the tumour did not progress within 6 months after the therapy was terminated), previous treatment with a direct KRASG12C inhibitor, systemic anticancer therapy within 28 days of study day 1, and therapeutic or palliative radiation therapy within 2 weeks of treatment initiation. We randomly assigned (1:1) patients to oral sotorasib (960 mg once daily) or intravenous docetaxel (75 mg/m2 once every 3 weeks) in an open-label manner using interactive response technology. Randomisation was stratified by number of previous lines of therapy in advanced disease (1 vs 2 vs >2), ethnicity (Asian vs non-Asian), and history of CNS metastases (present or absent). Treatment continued until an independent central confirmation of disease progression, intolerance, initiation of another anticancer therapy, withdrawal of consent, or death, whichever occurred first. The primary endpoint was progression-free survival, which was assessed by a blinded, independent central review in the intention-to-treat population. Safety was assessed in all treated patients. This trial is registered at ClinicalTrials.gov, NCT04303780, and is active but no longer recruiting. Findings Between June 4, 2020, and April 26, 2021, 345 patients were randomly assigned to receive sotorasib (n=171 [50%]) or docetaxel (n=174 [50%]). 169 (99%) patients in the sotorasib group and 151 (87%) in the docetaxel group received at least one dose. After a median follow-up of 17·7 months (IQR 16·4–20·1), the study met its primary endpoint of a statistically significant increase in the progression-free survival for sotorasib, compared with docetaxel (median progression-free survival 5·6 months [95% CI 4·3–7·8] vs 4·5 months [3·0–5·7]; hazard ratio 0·66 [0·51–0·86]; p=0·0017). Sotorasib was well tolerated, with fewer grade 3 or worse (n=56 [33%] vs n=61 [40%]) and serious treatment-related adverse events compared with docetaxel (n=18 [11%] vs n=34 [23%]). For sotorasib, the most common treatment-related adverse events of grade 3 or worse were diarrhoea (n= 20 [12%]), alanine aminotransferase increase (n=13 [8%]), and aspartate aminotransferase increase (n=9 [5%]). For docetaxel, the most common treatment-related adverse events of grade 3 or worse were neutropenia (n=13 [9%]), fatigue (n=9 [6%]), and febrile neutropenia (n=8 [5%]). Interpretation Sotorasib significantly increased progression-free survival and had a more favourable safety profile, compared with docetaxel, in patients with advanced NSCLC with the KRASG12C mutation and who had been previously treated with other anticancer drugs. Funding Amgen." @default.
• W4319337483 created "2023-02-08" @default.
• W4319337483 creator A5001684767 @default.
• W4319337483 creator A5002718160 @default.
• W4319337483 creator A5003642180 @default.
• W4319337483 creator A5011828578 @default.
• W4319337483 creator A5011868198 @default.
• W4319337483 creator A5015990073 @default.
• W4319337483 creator A5016567527 @default.
• W4319337483 creator A5018835840 @default.
• W4319337483 creator A5019052781 @default.
• W4319337483 creator A5025511599 @default.
• W4319337483 creator A5028699633 @default.
• W4319337483 creator A5036507802 @default.
• W4319337483 creator A5038343178 @default.
• W4319337483 creator A5040544006 @default.
• W4319337483 creator A5044610238 @default.
• W4319337483 creator A5046400988 @default.
• W4319337483 creator A5047467702 @default.
• W4319337483 creator A5048517627 @default.
• W4319337483 creator A5049294543 @default.
• W4319337483 creator A5051003108 @default.
• W4319337483 creator A5052608673 @default.
• W4319337483 creator A5052765751 @default.
• W4319337483 creator A5053359739 @default.
• W4319337483 creator A5055246540 @default.
• W4319337483 creator A5057162992 @default.
• W4319337483 creator A5063300526 @default.
• W4319337483 creator A5071005996 @default.
• W4319337483 creator A5071799615 @default.
• W4319337483 creator A5087199549 @default.
• W4319337483 creator A5087736735 @default.
• W4319337483 creator A5088178599 @default.
• W4319337483 creator A5090324173 @default.
• W4319337483 date "2023-03-01" @default.
• W4319337483 modified "2023-10-18" @default.
• W4319337483 title "Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial" @default.
• W4319337483 cites W1839238860 @default.
• W4319337483 cites W1994225895 @default.
• W4319337483 cites W2018143015 @default.
• W4319337483 cites W2080663986 @default.
• W4319337483 cites W2106789440 @default.
• W4319337483 cites W2120377396 @default.
• W4319337483 cites W2128339707 @default.
• W4319337483 cites W2130652363 @default.
• W4319337483 cites W2134667653 @default.
• W4319337483 cites W2140980839 @default.
• W4319337483 cites W2170030318 @default.
• W4319337483 cites W2170568643 @default.
• W4319337483 cites W2172010139 @default.
• W4319337483 cites W2305475210 @default.
• W4319337483 cites W2465450966 @default.
• W4319337483 cites W2778540293 @default.
• W4319337483 cites W2886464002 @default.
• W4319337483 cites W2906754611 @default.
• W4319337483 cites W2914792906 @default.
• W4319337483 cites W2917387482 @default.
• W4319337483 cites W2982321167 @default.
• W4319337483 cites W3165227719 @default.
• W4319337483 cites W3166520558 @default.
• W4319337483 cites W3167619469 @default.
• W4319337483 cites W3172081492 @default.
• W4319337483 cites W4205501618 @default.
• W4319337483 cites W4220828402 @default.
• W4319337483 cites W4221134810 @default.
• W4319337483 cites W4297075058 @default.
• W4319337483 doi "https://doi.org/10.1016/s0140-6736(23)00221-0" @default.
• W4319337483 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36764316" @default.
• W4319337483 hasPublicationYear "2023" @default.
• W4319337483 type Work @default.
• W4319337483 citedByCount "46" @default.
• W4319337483 countsByYear W43193374832023 @default.
• W4319337483 crossrefType "journal-article" @default.
• W4319337483 hasAuthorship W4319337483A5001684767 @default.
• W4319337483 hasAuthorship W4319337483A5002718160 @default.
• W4319337483 hasAuthorship W4319337483A5003642180 @default.
• W4319337483 hasAuthorship W4319337483A5011828578 @default.
• W4319337483 hasAuthorship W4319337483A5011868198 @default.
• W4319337483 hasAuthorship W4319337483A5015990073 @default.
• W4319337483 hasAuthorship W4319337483A5016567527 @default.
• W4319337483 hasAuthorship W4319337483A5018835840 @default.
• W4319337483 hasAuthorship W4319337483A5019052781 @default.
• W4319337483 hasAuthorship W4319337483A5025511599 @default.
• W4319337483 hasAuthorship W4319337483A5028699633 @default.
• W4319337483 hasAuthorship W4319337483A5036507802 @default.
• W4319337483 hasAuthorship W4319337483A5038343178 @default.
• W4319337483 hasAuthorship W4319337483A5040544006 @default.
• W4319337483 hasAuthorship W4319337483A5044610238 @default.
• W4319337483 hasAuthorship W4319337483A5046400988 @default.
• W4319337483 hasAuthorship W4319337483A5047467702 @default.
• W4319337483 hasAuthorship W4319337483A5048517627 @default.
• W4319337483 hasAuthorship W4319337483A5049294543 @default.
• W4319337483 hasAuthorship W4319337483A5051003108 @default.
• W4319337483 hasAuthorship W4319337483A5052608673 @default.
• W4319337483 hasAuthorship W4319337483A5052765751 @default.
• W4319337483 hasAuthorship W4319337483A5053359739 @default.
• W4319337483 hasAuthorship W4319337483A5055246540 @default.
• W4319337483 hasAuthorship W4319337483A5057162992 @default.

• next